Since promising, targeted, therapeutic strategies are upcoming for SOD1-ALS [5], the study of the neurodegenerative process associated with this genetic form of ALS through PET imaging can provide potentially useful biomarkers to understand disease pathogenesis and to track the disease course in clinical trials, in both asymptomatic and symptomatic mutation carriers. Here, SOD1 is linked to amyotrophic lateral sclerosis.